A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
A Phase 1 Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder in Chronic Smokers and People With Mild or Moderate Asthma Compared to Healthy Volunteers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
North Dartmouth, Massachusetts, United States, 02747
- Site #103
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68502
- Site #102
-
-
Texas
-
Dallas, Texas, United States, 75247
- Site #101
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- eligible subjects will be men or women aged 18 to 65 years inclusive;
- body mass index (BMI) 18 to 30 kg/m2;
- healthy adults must be in general good health with no clinically significant abnormalities that would affect ability to complete study.
- subjects with asthma must be non-smokers who have a forced expiratory volume in one second (FEV1) ≥ 60% of predicted for race, age, sex, and height;
- subjects who smoke must have at least a 12-month, 0.5 pack of cigarettes per day history or the equivalent consumption of cigars and a positive result for plasma cotinine.
Exclusion Criteria:
- subjects with asthma will be excluded for more than 2 hospitalizations or emergency room visits, or more than 3 courses of systemic steroids in the past 12 months or 1 course within the past 8 weeks for respiratory illness;
- asthma exacerbation within 8 weeks of before screening;
- unscheduled or urgent visit to any medical facility for asthma-related problems within 8 weeks before screening;
- history of intubation or intensive care unit admission for asthma in the past 5 years.
- Subjects who smoke will be excluded if they have intrinsic lung disease including asthma or chronic obstructive pulmonary disease (COPD) with an FEV1 of <60% of predicted and a score of ≥2 on the Medical Research Council Dsypnea Scale (MRC);
- any cardiovascular risk factor or contraindication for the use of triptans
- use of nonselective monamine oxidase inhibitors (MAOI), serotonin reuptake inhibitors (SSRIs), propranolol, or cimetidine within 4 weeks prior to the Screening Visit, or planned use during the study;
- positive serology test (hepatitis B virus surface antigen [HBsAg], hepatitis C virus [HCV] antibody, human immunodeficiency virus [HIV] 1 & 2 antibodies).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Adult Asthmatics
Two doses of CVT-427, 2 hours apart.
3.0 mg zolmitriptan capsule administered via CVT-427 breath-actuated inhaler in adult asthmatics
|
Each subject received 2 self-administered doses of 3.0 mg CVT-427 (zolmitriptan inhalation powder), 2 hours apart.
|
|
Experimental: Adult Smokers
Two doses of CVT-427, 2 hours apart.
3.0 mg zolmitriptan capsule administered via CVT-427 breath-actuated inhaler in adult smokers.
|
Each subject received 2 self-administered doses of 3.0 mg CVT-427 (zolmitriptan inhalation powder), 2 hours apart.
|
|
Experimental: Adult Healthy Volunteers
Two doses of CVT-427, 2 hours apart.
3.0 mg zolmitriptan capsule administered via CVT-427 breath-actuated inhaler in adult healthy volunteers.
|
Each subject received 2 self-administered doses of 3.0 mg CVT-427 (zolmitriptan inhalation powder), 2 hours apart.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in measure of pulmonary function via Spirometry
Time Frame: within 1 hour prior to dose and up to 24 hours post-dose.
|
within 1 hour prior to dose and up to 24 hours post-dose.
|
|
Maximum observed plasma drug concentration (Cmax)
Time Frame: up to 24 hours post-dose.
|
up to 24 hours post-dose.
|
|
Maximum observed plasma drug concentration (tmax)
Time Frame: up to 24 hours post-dose.
|
up to 24 hours post-dose.
|
|
Area under the concentration time curve over the dosing interval (AUC0-last)
Time Frame: up to 24 hours post-dose.
|
up to 24 hours post-dose.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of subjects with Adverse Events (AEs) including Serious AEs
Time Frame: up to 5 days
|
up to 5 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Charles Oh, MD, Acorda Therapeutics
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TRIP-PK-1041
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.